Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2020-05-19 Call Transcript
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of Cipla Limited's Q4 FY20 earnings conference call held on May 15, 2020. It includes management commentary, financial performance details, operational updates, and forward-looking statements. The presence of a moderator, multiple company executives, and a Q&A format typical of earnings calls is evident. The document is not merely an announcement or a brief summary but a full transcript of the call. Therefore, it fits the category of a Call Transcript (CT).
2020-05-19 English
Please find enclosed copy of the transcript of the Company's Q4 FY20 earnings conference call dated 15th May, 2020. The transcript is also available on the Company''''s website i.e. www.cipla.com ....
Regulatory Filings
2020-05-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated 19 May 2020, addressed to stock exchanges and a Luxembourg stock exchange, informing about the schedule of analyst and institutional investor meetings. It references regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events and information. The content is a notification of upcoming investor meetings, not a financial report, earnings release, or detailed presentation. The document length is only 1721 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-05-19 English
Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed schedule of Analyst / Institutional ..
Regulatory Filings
2020-05-19 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing Cipla's filing of an Abbreviated New Drug Application (ANDA) for a generic version of GSK's Advair Diskus with the USFDA. It includes details about the product, clinical study completion, market context, and company comments. There are no financial statements, regulatory certifications, or detailed financial data. The document is an announcement of a corporate development related to product filing and clinical progress, not a financial report or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a significant business development impacting the company's product pipeline and market strategy.
2020-05-18 English
Press Release - Cipla files ANDA for generic version of GSK's Advair Diskus ®
Regulatory Filings
2020-05-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.